Literature DB >> 6477352

The expression of tumor-associated antigens in primary and metastatic human malignant melanoma.

J Brüggen, E B Bröcker, L Suter, K Redmann, C Sorg.   

Abstract

Monoclonal antibodies were raised against cultured melanoma cells and selected for their reactivity with melanoma-associated antigens expressed on various melanoma lines. Of 34 monoclonal antibodies, which were all reacting with melanoma lines only 19 antibodies bound to fresh melanoma tissue. Of the 19 antibodies 10 displayed a broad cross-reactivity with normal cells and structures, whereas 9 had a restricted reactivity. Of these antibodies five types were defined, which detected antigens (nevocellular I, nevocellular II, neural, endothelial, basal cell), which were found on certain normal tissues and structures and on certain tumor phenotypes. On the basis of an extensive study on melanoma biopsies of different stages it became evident, that the endothelial, the basal cell and also HLA-DR antigens were significantly more expressed in high risk melanomas. The basal cell antigen was preferentially expressed in locoregional metastases. By immunization with fresh melanoma biopsies different specificities of monoclonal antibodies were obtained as compared to immunization with established cell lines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6477352

Source DB:  PubMed          Journal:  Behring Inst Mitt        ISSN: 0301-0457


  4 in total

1.  Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma.

Authors:  M Munzarová; D Zemanová; J Kovarík; Z Pacovský; A Rejthar; J Bártek
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

2.  Metastatic human melanoma. Phenotypic heterogeneity and antigen expression in relation to the clinical status.

Authors:  L Suter; E B Bröcker; H Ostmeier; J Schumann; C Sorg
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

3.  Selective toxicity of neocarzinostatin-monoclonal antibody conjugates to the antigen-bearing human melanoma cell line in vitro.

Authors:  G Lüders; W Köhnlein; C Sorg; J Brüggen
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  Criteria for selecting monoclonal antibodies with respect to accumulation in melanoma tissue.

Authors:  S Matzku; J Brüggen; E B Bröcker; C Sorg
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.